Multi-center phase II trial of bortezomib and rituximab maintenance combination therapy in patients with mantle cell lymphoma after consolidative autologous stem cell transplantation

BACKGROUND: Mantle cell lymphoma (MCL) is an aggressive and incurable lymphoma. Standard of care for younger patients with MCL is induction chemotherapy followed by autologous stem cell transplantation (auto-HCT). Rituximab maintenance after auto-HCT has been shown to improve progression-free surviv...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Robert W., Palmer, Joycelynne M., Tomassetti, Sarah, Popplewell, Leslie L., Alluin, Jessica, Chomchan, Pritsana, Nademanee, Auayporn P., Siddiqi, Tanya, Tsai, Ni-Chun, Chen, Lu, Zuo, Fay, Abary, Rosemarie, Cai, Ji-lian, Herrera, Alex F., Rossi, John J., Rosen, Steven T., Forman, Stephen J., Kwak, Larry W., Holmberg, Leona A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022297/
https://www.ncbi.nlm.nih.gov/pubmed/29954415
http://dx.doi.org/10.1186/s13045-018-0631-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6022297/
https://www.ncbi.nlm.nih.gov/pubmed/29954415
http://dx.doi.org/10.1186/s13045-018-0631-3

Ejemplares similares